Lupin gets four USFDA inspection for its Tarapur manufacturing facility

6 Apr 2022 , 02:57 PM

The USFDA has concluded an inspection at Lupin’s Tarapur manufacturing facility. The inspection was carried out between March 22, 2022 and April 4, 2022.

Further, the inspection closed with four observations. “We are confident of addressing the observations to the U.S. FDA’s satisfaction. We are committed to adherence and full compliance with CGMP regulations and uphold the highest quality standar;ds across our manufacturing sites”, said pharma-major Lupin in a regulatory filing.

At around 2:59 PM, Lupin was trading at Rs772.05 apiece down by Rs5.95 or 0.76% on the BSE.